Latest Licensing News

Li-S Energy has narrowed its FY26 loss and reached several commercialisation milestones, including a 2C Power Cell, international shipping approvals and its first lithium foil sale. But the ASX battery developer still needs customer offtake and fresh funding before its proposed 1 GWh manufacturing expansion can become reality.

Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.

TG Metals has outlined a preliminary A$26.8 million pre-tax NPV for a low-capital heap leach operation at its Van Uden Gold Project in Western Australia. The economics are striking, but the study remains an early-stage assessment reliant on further drilling, approvals, financing and technical work.

Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.

Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.

WT Financial Group has delivered its sixth consecutive year of growth, with EBITDA rising 19.5% to $8.2 million and operating cash flow reaching $10.3 million. The ASX-listed advice network is now shifting from building scale to monetising its B2B platform and Hubco investments, while carrying higher provisions and debt.

Me Today reported a NZ$2.66 million FY26 profit, but the result was dominated by a NZ$4.12 million gain from losing control of King Honey. The remaining business grew revenue and improved its operating loss, yet continued to consume cash and will rely on October warrant funding.

Cobalt Blue has cleared important technical and regulatory hurdles at its Kwinana refinery, but the pre-revenue developer says further funding is needed and auditors flagged material uncertainty over its ability to continue as a going concern. The company reported an A$8.797 million loss for FY2026 despite ending the year with A$4.265 million in cash.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Dimerix has drawn A$17 million from a non-dilutive facility, giving the biotech funding it says is sufficient to complete the ACTION3 Phase 3 trial of DMX-200 and continue developing DMX-652. A further A$17 million remains available, although repayment depends partly on future licensing income, milestones or capital-market access.

Bounty Oil & Gas NL (ASX:BUY) is pursuing a 2,322 km² deepwater exploration block offshore Liberia, backed by a $3.55 million placement and major vendor-linked securities. The opportunity remains conditional: the block has no executed production sharing contract, no independent resource estimate and has not yet been reviewed directly by Bounty.

Future Metals has reshaped its Panton development plan around a potentially lower-capital Savannah processing route, but entered FY27 with only A$1.46 million in cash and a formal warning over future funding. A post-year-end A$3.56 million raising now funds the next study phase, including a larger updated resource base.